Improving the global competitiveness of the UK in commercial clinical trials is a key component of the Government’s Life Sciences agenda, and a central aim of the NIHR Clinical Research Network. Improving the performance of commercial studies – delivering the agreed number of recruits within an agreed timescale to the highest standards – has been a key target for DeNDRoN and the rest of the NIHR Clinical Research Network since it was established.
Latest figures published by the NIHR show that DeNDRoN now leads the way in performance of its industry studies, with 80% being delivered on time to target.
Professor Ian McKeith, DeNDRoN director for industry says, “A few years ago only 40% of commercial studies completed on time to target and our industry partners have been very clear that this wasn’t acceptable. We have worked really hard over the past few years to put in place the capacity and systems, locally and nationally, to improve performance in this area. This starts with working with companies as early as possible in the study life cycle to support good feasibility assessment and site selection. We then ensure that delivery is closely monitored so that issues can be identified as early as possible. The processes we use for helping to resolve issues and ensure delivery are really just common sense: supporting sharing of local knowledge and expertise between sites, and deploying extra resources where necessary”.
Lilly’s Clinical Development Consultant, Annabelle Hickman sung high praise of DeNDRoN throughout the GERAS study,“Lilly are delighted with the UK performance. I believe this study demonstrates the great things that can be achieved with solid upfront planning, a positive attitude, motivation and effective partnering between sponsor, Network and sites. I’m in no doubt DeNDRoN played a critical role in driving delivery.”
